| Trial ID: | L3313 |
| Source ID: | NCT00287066
|
| Associated Drug: |
Inhaled Human Insulin
|
| Title: |
A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Inhaled Human Insulin|DRUG: Regular Human Insulin
|
| Outcome Measures: |
Primary: 18F-labeled glucose uptake in muscle | Secondary: Glucose turnover overnight Insulin pharmacokinetics
|
| Sponsor/Collaborators: |
Sponsor: Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
22
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-02
|
| Completion Date: |
2007-03
|
| Results First Posted: |
|
| Last Update Posted: |
2008-02-21
|
| Locations: |
Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00287066
|
